Zaid Admani

Now here's where it gets a little technical, but stick with me here.

Compounding pharmacies are allowed to make copycat versions of drugs when there's a shortage.

And for a long time, that was the case for GLP-1s, demand massively outpaced supply.

But now that Eli Lilly and Nova Nordisk have ramped up production, there is no more shortage, so these compounding pharmacies are supposed to stop mass producing the copies.

But there is an exception for a very limited case, like customized patient-specific doses.

And it's this gray area where all the fighting is happening right now.

Strive feels like they should be allowed to make these patient-specific GLP-1s.

But late last year, Eli Lilly actually sued Strive, accusing the pharmacy of falsely marketing its compound drugs as personalized.

bad blood there, and now it's escalating into a full-blown antitrust lawsuit.

Now, one thing that you got to keep in mind is that the patent for these drugs don't last forever.

In fact, Novonordis is already feeling the pressure.

The patent for its semi-glutide, which is the active ingredient in Ozempic and Wegovy, are already expiring in several countries outside the US, opening the door for regulated generics to enter the market.

Now, in the US and UK, Novonordis still has a few years of production left.

Eli Lilly has a bit more runway here about a decade before their patents start expiring on Manjaro and Zetbound.

So as you can imagine, Eli Lilly and Nova Nordisk want to capitalize on their patent for as long as they have it and shut down these copycat compounding pharmacies from taking market share.

So I wouldn't be surprised if we keep seeing more lawsuits about this because Eli Lilly and Nova Nordisk have a short window to capitalize on their patent.

Let's shift gears and talk about Netflix.

Netflix continues to make big content moves as they're in the middle of an $80 billion takeover of Warner Brothers.

This week, Netflix signed a deal to expand their partnership with Sony Pictures.

Under this new multi-year agreement worth about $7 billion, Netflix will become the exclusive global streaming home for Sony films after they finish their theatrical run and video on-demand window.